As a service provider for innovation-supporting measures under the Medical Technology Programme of the German Federal Ministry of Research, Technology & Space (BMFTR), we highly welcome the COM proposal to reform MDR and IVDR. Generating clinical evidence through clinical investigations for medical devices is key, but costly.
innoVance GmbH
Company · Germany
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track innoVance in PolicySpeak: request access →
Work at innoVance GmbH? so we know who speaks for it.
Their record over time
innoVance GmbH filed 2 positions between 27 Apr 2026 and 5 May 2026, across 1 of the 326 legislative files tracked here.
What they argued
Art. 82 MDR Handling of other clinical investigations As a service provider for innovation-supporting measures under the Medical Technology Programme of the German Federal Ministry of Research, Technology and Space (BMFTR), we welcome the COM proposal to reform the MDR and IVDR. The Commission proposes the complete removal of Article 82 MDR on other clinical investigations.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Is this your organization?
Everything on this page comes from innoVance GmbH’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.